Koers Vicore Pharma Holding AB Nasdaq Stockholm
Aandelen
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- SEK | - |
Omzet 2024 * | 52 mln. 4,81 mln. 4,47 mln. | Omzet 2025 * | 393 mln. 36,35 mln. 33,77 mln. | Marktkapitalisatie | 2,15 mld. 199 mln. 185 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -221 mln. -20,43 mln. -18,98 mln. | Nettowinst (verlies) 2025 * | -166 mln. -15,35 mln. -14,26 mln. | EV/omzet 2024 * | 35,4 x |
Nettoliquiditeiten 2024 * | 306 mln. 28,31 mln. 26,3 mln. | Nettoliquiditeiten 2025 * | 222 mln. 20,51 mln. 19,05 mln. | EV/omzet 2025 * | 4,9 x |
K/w-verhouding 2024 * |
-14,2
x | K/w-verhouding 2025 * |
-8,61
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,02% |
Recentste transcriptie over Vicore Pharma Holding AB
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ahmed Mousa
CEO | Chief Executive Officer | 40 | 09-09-23 |
Hans Jeppsson
DFI | Director of Finance/CFO | - | 01-01-17 |
Elin Rosendahl
CTO | Chief Tech/Sci/R&D Officer | - | 16-11-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 57 | 01-01-18 | |
Director/Board Member | 66 | 01-01-18 | |
Michael Buschle
BRD | Director/Board Member | 64 | 01-01-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |
- Beurs
- Aandelen
- Koers VICO
- Koers